Objectives Socioeconomic factors are important components of Health Technology Assessment’s (HTA) institutionalization. If most of the countries have established HTA agencies, they required scientific expertise to emerge and become institutionalized (Banta, 2003). In a previous scientometric work, we did an analysis of scientific conditions of HTA emergence in the scientific literature (Benoit, 2013). Our observation allowed us to link HTA research capacity and HTA institutionalization in a given country.  Methods In order to explore endogenous as well exogenous factors sustaining HTA expertise, we undertake a principal component analysis as multivariate analysis technique in order to establish which variable are more appropriate for the assessment of scientific expertise in the context of HTA public policy (Vyas, 2009). Results HTA national public policy could be ranked according to their academic expertise. Country HTA publications productivity matched in comparison with health expenses & gross product in several countries. Nevertheless this ranking doesn’t tell us why some country like UK perform well while others like France don’t. Conclusion Our results underline the country difference of arbitration between public policies such as public health, and industrial or innovation policy (Gorry, 2011). Among tested variables, it appears that the regulation of drug pricing and market access, or the macroeconomic impact of pharmaceutical industry in a country contribute to determine the scope of HTA policies.  References - Banta D., (2003), The development of health technology assessment, Health Policy, 63, 121-132. - Benoit C. & Gorry P., (2013), The scientific-knowledge based institutionalization of Health Technology Assessment: a bibliometric & network analysis, 10th Annual Meeting HTAi Seoul. - Vyas S. & Kumaranayake L., (2006), Constructing socio-economic status indices: how to use principal components analysis, Health Policy and Planning, 21, 459-468. - Gorry P. et al., (2011), Reinstitutionalizing the evaluation of medicines: EU-national complementarities, competition and contradictions, ECPR conference, Reykjavik.